

**Supplementary Table. 3. Mice allocation in HCV infection cohort<sup>S</sup>**

	cohort	notes	12 h	2 d	4 d	1 w	2 w	3 w	1 m	2 m	3 m	4 m	6 m	10 m	12 m	E	P	N
Batch 1	ICR-C/O <sup>Tg</sup>		2	2	3	2	4	2	4	3	3	1	1	1	1	2*, 6 <sup>#</sup>	2	33
	WT		2	2	2	2	2	2	1	1	1	1	1	1	2			
Batch 2	ICR-C/O <sup>Tg</sup>	J399EM		2	2	3	4	3	4	2	1	2	1	1	1	1*, 5 <sup>#</sup>	3	30
	WT			1	1	1	1	1	1	1	1	1	1	1	1			
Batch 3	ICR-C/O <sup>Tg</sup>			2	2	2	2	2	3	1	1	2	1	1	1	3 <sup>#</sup>	1	21
	WT			1	1	1	1	1	1	1	1	1	1	1	1			
				1 w	2 w													
Batch 4	ICR-C/O <sup>Tg</sup>	Human serum(1b)		3	3													6
	ICR-C/O <sup>Tg</sup>	Human serum(2a)		3	3													6
	ICR-C/O <sup>Tg</sup>	con1/JFH1		3	3													6
Batch 5	ICR-C/O <sup>Tg</sup>	Gradient dose(J399EM)			9													9
				1 w	2 w	3 w												
Batch 6 <sup>&amp;</sup>	ICR-C/O <sup>Tg</sup>	DMSO(J399EM)		3	3	3												
	ICR-C/O <sup>Tg</sup>	VX-950(J399EM)		3	3	3												
				2 d	1 w	2 w												
Batch 7	B6-C/O <sup>Tg</sup>	J399EM		3	3	3												
	ICR-C/O <sup>Tg</sup>			3	3	3												
				6 h	12 h	24 h	48 h	96 h	1 w	2 w	3 w	1 m						
Batch 8	ICR-C <sup>Tg</sup>	J399EM		3	3	3	3	3	3	3	3	3						
	ICR-C/O <sup>Tg</sup>			3	3	3	3	3	3	3	3	3	3					
				12 h	2 w	1 m	2 m	6 m	10 m									
Batch 9	ICR-C/O <sup>Tg</sup>	JFH1		1	1	1	1	1	1									

P: prolonged observation; E: number of excluded mice; N: number of mice in the batch.

\* death due to fulminant hepatitis or unknown reasons;

<sup>#</sup> negative for viral load in liver at the time of assay.

<sup>&</sup> VX-950 treatment started from 1w post HCV infection.

<sup>S</sup> Mice were sacrificed at the indicated time for liver or spleen biopsy, and blood was collected (~0.4 mL sera) for viral load analysis. Before termination, each mouse was bled (~50uL) at each prior time point for analysis of serology, serum chemistry or inflammatory cytokines profiling.